Bruker has acquired Canopy Biosciences, which specialises in high multiplex biomarker imaging for immunology, immuno-oncology and cell therapy.
The acquisition will boost Bruker’s offering in targeted multi-omics and fluorescence-based imaging techniques.
Established in 2016, Canopy owns a portfolio of products and services designed for gene editing, gene expression analysis and regulation, and bioprocessing.
Its gene editing portfolio consists of CRISPR kits and full-service custom cell line engineering.
Additionally, Canopy has a multi-omic platform for immune profiling, including ultrasensitive DNA sequencing (RareSeq), RNAseq, and gene expression analysis. The platform also enables multiplexed protein detection in cells and tissue samples through ChipCytometry.
Bruker NANO Group president Dr Mark Munch said: “We are excited to add the multi-omics and high-content cytometry expertise of Canopy and its novel ChipCytometry platform to Bruker.
“Canopy has a unique set of products that enable single cell, tissue and suspended cell-based discovery and validation in immunology and targeted proteomics, as well as a suite of complementary multi-omics services.”
The global reach, complementary technologies and applications knowledge of Bruker is expected to help Canopy further build its business.
Canopy Biosciences CEO Dr Edward Weinstein said: “Joining forces with a leading life-science tools provider with broad geographic reach enables us to give many more researchers access to our powerful high-plex ChipCytometry platform, designed for accelerating basic immunology and clinical research, as well as biopharma drug development.”
Bruker develops and manufactures scientific instruments and analytical and diagnostic solutions, which enable scientists to explore life and materials at molecular, cellular and microscopic levels.
In July, Bruker partnered with Inscopix for its new multimodal image registration and analysis platform.
In August 2018, the company acquired a majority stake in Hain Lifescience, an infectious disease-focused molecular diagnostics (MDx) company in Germany, for an undisclosed amount.